Peptide Active Stability in O/W and W/O Emulsions — The Constraints Formulators Actually Hit

Most cosmetic peptide actives are water-soluble. Most finished cosmetic products are emulsions — either oil-in-water (lotion / serum / lighter creams) or water-in-oil (richer creams / occlusive treatments). Incorporating a water-soluble active into a partly-oil-phase system creates specific stability and bioavailability challenges that don't show up in pure aqueous formulations.

Where the peptide actually sits in an emulsion

In an oil-in-water (O/W) emulsion, the continuous phase is water and the oil droplets are dispersed within. A water-soluble peptide active dissolved in the water phase before emulsification ends up in the continuous water phase, with negligible partition into the oil droplets. The peptide is dispersed at the formula concentration throughout the continuous phase.

In a water-in-oil (W/O) emulsion, the continuous phase is oil and the water droplets are dispersed within. A water-soluble peptide dissolves in the internal water phase, which is now compartmentalized inside small droplets within the continuous oil phase. The peptide is concentrated in the water droplets; the bulk of the formula (the oil continuous phase) contains essentially no peptide.

This distinction matters for both stability and bioavailability:

• O/W stability: the peptide is exposed to the full continuous aqueous phase, with all of its pH, antimicrobial preservation, and dissolved-oxygen properties. The peptide can interact with anything else dissolved in the water phase (chelators, reductants, other actives, salt counter-ions).
• W/O stability: the peptide is sequestered in droplets, which can be protective (less exposure to the antimicrobial system, less exposure to dissolved oxygen if the formulation is anti-oxidant) but also creates concentration gradients that drive Ostwald ripening or coalescence over shelf life.
• Bioavailability: an O/W emulsion delivers peptide to skin in the continuous aqueous phase that wets the stratum corneum directly. A W/O emulsion delivers peptide as a sequestered cargo that releases on emulsion breakdown at the skin surface; the release kinetics depend on the emulsion's specific composition.

Stability issues specific to peptide-in-emulsion

### 1. pH drift over shelf life

The emulsion pH at day zero is the pH of the continuous water phase. Over months, pH can drift due to: - Hydrolysis of ester-based emulsifiers releasing fatty acids - Oxidation of unsaturated lipids generating acidic degradation products - Microbial growth (if the preservation system fails locally) generating organic acids

A pH drift of even 0.5 units can pull a Cu-peptide complex outside its working window. The mitigation: use a buffered formulation, test pH stability across the full shelf life, and select emulsifiers with low hydrolysis tendency.

### 2. Interaction with the emulsifier system

Non-ionic emulsifiers (PEG-based, glyceryl-based, sucrose-based) are generally peptide-compatible. Ionic emulsifiers create specific issues: - Anionic emulsifiers (carboxylates, sulfates) can interact with positively charged residues (Lys, Arg, free N-terminus) on cationic peptides, with the peptide partially adsorbing to droplet surfaces and changing its bioavailability - Cationic emulsifiers (quaternary ammoniums) can interact with negatively charged residues (Asp, Glu, C-terminus) on anionic peptides

For complex peptides with mixed charge profiles (most natural sequences), the ionic emulsifier interaction is hard to predict without empirical testing.

### 3. Preservative interaction

Most peptide actives interact in some way with cosmetic preservatives: - Parabens (methylparaben, propylparaben) — generally peptide-compatible - Phenoxyethanol — generally peptide-compatible at typical use levels - Benzyl alcohol + dehydroacetic acid combinations — can interact with some peptides via hydrogen bonding to the peptide backbone; usually not a critical issue but worth testing - Sodium benzoate / potassium sorbate — generally peptide-compatible - Caprylyl glycol + ethylhexylglycerin — generally peptide-compatible

The risk is not in the preservative concentration (typically < 1% w/w) but in any specific interaction that the published literature for the peptide doesn't yet describe. New combinations need real testing.

### 4. Free metal ions

Free Cu²⁺ from a Cu-peptide complex breakdown, free Fe³⁺ from trace contamination, or free Zn²⁺ from a separate active in the formulation can all destabilize sensitive peptides via oxidation of Met, Cys, and Trp residues. The mitigation: - Avoid EDTA (which would also strip the Cu from a Cu-peptide complex if present) - Use phytic acid or other low-affinity Cu-specific chelators at very low concentrations to scavenge free Cu²⁺ without disrupting the Cu-peptide equilibrium - Source raw materials with low transition-metal contamination (cosmetic-grade water at typical < 10 ppb total transition metals is acceptable for most peptide formulations; reagent-grade water may be needed for sensitive peptides)

### 5. Droplet-size driven Ostwald ripening

In W/O emulsions, the peptide concentration in droplets drives water-phase equilibration over time. Small droplets with high curvature lose water (and the peptide concentrates); larger droplets gain water. Over a 24-month shelf life, this can reorganize the spatial distribution of the active in the emulsion in ways that change release kinetics.

The mitigation: produce a tight droplet-size distribution at manufacture (high-shear emulsification with controlled energy input) and validate stability with a sized-fraction analysis rather than just bulk parameters.

The formulation patterns that work

The patterns that consistently produce stable peptide emulsions through real-time shelf life:

1. **Pre-dissolve the peptide in chelator-free buffer**, then add to the water phase before emulsification. This ensures the peptide is in solution before any emulsion shear is applied.
2. **Use non-ionic emulsifiers** as the primary system, with ionic co-surfactants only when specifically needed for texture or stability and at minimum concentrations.
3. **Buffer the formulation to the peptide's stability window** with a low-ionic-strength buffer (citrate at pH 5-6 is a common choice for Cu-peptide formulations).
4. **Add the peptide in the cool-down phase**, below 40 °C, to avoid heat-induced degradation.
5. **Use airless packaging** (airless pump, sachet, or inert-gas-flushed) to limit oxygen exposure over shelf life.
6. **Validate with accelerated stability** at 40 °C / 75% RH for 6-8 weeks, with periodic pulls measuring active content (HPLC), pH, viscosity, organoleptic, and microbiology. Confirm the projection with real-time stability at 25 °C / 60% RH out to the labeled shelf life.

What Pepoderma provides for emulsion product development

The standard release packet for Pepoderma cosmetic-grade peptide actives includes: - Solubility data in water at typical formulation concentrations - pH-stability data for the active across the working window - Recommended preservation system compatibility flags

On request for brands developing emulsion products: - Compatibility screening in a reference O/W or W/O emulsion matrix supplied by the brand, with stability pulls at 0/2/4/8 weeks accelerated and 0/3/6/12 months real-time - Emulsifier-system flagging based on the active's charge profile and known interactions - Real-time formulation review during brand R&D — typically a 30-minute call between our regulatory/formulation team and the brand's chemist to flag predictable issues before they show up at stability testing

The cost of identifying an emulsion-active incompatibility early is much lower than the cost of finding it at month 6 of accelerated stability after the brand has committed to artwork and packaging.